InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: trading.jeff post# 40747

Sunday, 10/29/2017 11:30:59 PM

Sunday, October 29, 2017 11:30:59 PM

Post# of 48316
Like Buffett, his name is stock moving so it is not surprising. I think he may actually have a larger stake in it too. Checkout guru focus article.

https://www.gurufocus.com/news/585917/steven-cohen-takes-57-stake-in-cancer-biopharma-oncosec

Steven Cohen (Trades, Portfolio), chairman and CEO of hedge fund Point72 Asset Management, bought OncoSec Medical Inc. (NASDAQ:ONCS), stretching his sizable positioning in the healthcare industry.

Cohen has 18.4% of Point72 Asset Management’s 809 long positions invested in the healthcare industry. The $187 billion portfolio of Point72 Asset Management is part of Cohen’s Point72, a family asset manager he opened after his former hedge fund, SAC Capital Advisors, was investigated for insider trading.

Point72 bought 5.7% of the company, consisting of 1.7 million shares, on Oct. 25. The transaction was valued around $1.96 million, though Cohen may have been the institutional investor the company said on Oct. 25 bought shares through a definitive purchase agreement.

A biopharmaceutical company, OncoSec Medical Inc. has developed an intratumoral cancer immunotherapy called ImmunoPulse that stimulates the immune system to attack tumors. The therapy has shown an acceptable safety profile and preliminary evidence of anti-tumor activity in various types of skin cancers, as well as the potential to initiate a systemic immune response without toxicities of other treatments.

OncoSec has four treatments in its pipeline. The closest, for metastatic melanoma, is in Phase II of a three-phase process for approval. Three others are in earlier stages.

The company had no revenue and net losses of $5.8 million, or 28 cents per share, compared to net losses of $6.6 million or 39 cents per share for fourth quarter fiscal 2017, which ended July 31.